Compare Mesoblast Limited (MESO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vistra Corp — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Vistra Corp trades at $159.21 (market cap $55.96B). The key difference: Vistra Corp is far larger — about 30.9× Mesoblast Limited's market cap, and Vistra Corp pays a 0.55% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Vistra Corp for 32 Days on average.
| MESO | VST | |
|---|---|---|
Market Cap | $1.81B | $55.96B |
Volume | 240,620 | 11,969,036 |
Sector | Health | Utilities |
52-Week High | $20.96 | $210.85 |
52-Week Low | $13.19 | $134.71 |
Typical Hold Time | 14 Days | 32 Days |
Enterprise Value | $1.89B | $77.89B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Vistra Corp. (VST) trades at $166.72, up 3.88% today, with a bullish technical signal and strong analyst support. The stock shows robust profitability with a net income margin of 11.55% and ROE of 75.73%, though earnings have been mixed recently. Recent developments include a $4.2 billion US loan to boost nuclear power and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook is positive given strategic positioning in AI power infrastructure, but risks include earnings volatility and high valuation multiples. The consensus price target of $215.23 implies significant upside, supported by institutional interest and favorable sector trends. Investors should weigh growth prospects against execution risks and market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
